ATE527995T1 - Medizinische saure cannabinoide - Google Patents

Medizinische saure cannabinoide

Info

Publication number
ATE527995T1
ATE527995T1 AT05704605T AT05704605T ATE527995T1 AT E527995 T1 ATE527995 T1 AT E527995T1 AT 05704605 T AT05704605 T AT 05704605T AT 05704605 T AT05704605 T AT 05704605T AT E527995 T1 ATE527995 T1 AT E527995T1
Authority
AT
Austria
Prior art keywords
acid
acidic cannabinoid
cbd
acid cannabinoids
cannabis
Prior art date
Application number
AT05704605T
Other languages
English (en)
Inventor
Henricus Korthout
Kitty Verhoeckx
Rentje Witkamp
Robert Doornbos
Mei Wang
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE527995T1 publication Critical patent/ATE527995T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
AT05704605T 2004-02-02 2005-02-02 Medizinische saure cannabinoide ATE527995T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04075300A EP1559423A1 (de) 2004-02-02 2004-02-02 Medizinisch anwendbare saure Cannabinoide
PCT/NL2005/000075 WO2005072719A1 (en) 2004-02-02 2005-02-02 Medicinal acidic cannabinoids

Publications (1)

Publication Number Publication Date
ATE527995T1 true ATE527995T1 (de) 2011-10-15

Family

ID=34639453

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05704605T ATE527995T1 (de) 2004-02-02 2005-02-02 Medizinische saure cannabinoide

Country Status (6)

Country Link
US (2) US7807711B2 (de)
EP (2) EP1559423A1 (de)
AT (1) ATE527995T1 (de)
ES (1) ES2375362T3 (de)
IL (1) IL177219A (de)
WO (1) WO2005072719A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
DE102007046086A1 (de) 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen
WO2010150245A1 (en) * 2009-06-24 2010-12-29 Tikun Olam Ltd. Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts
EP3834869B1 (de) 2010-12-22 2024-06-05 Syqe Medical Ltd. System zur wirkstofffreisetzung
NL2006621C2 (en) 2011-04-18 2012-10-22 Fytagoras B V New medical use for acidic cannabinoids.
KR101943821B1 (ko) * 2011-06-21 2019-01-31 한국전자통신연구원 무선 통신 시스템에서 제어채널 송수신 방법
ES2806034T3 (es) * 2011-09-29 2021-02-16 Thc Pharm Gmbh The Health Concept Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US20130274321A1 (en) * 2012-03-30 2013-10-17 Jon Newland Topical Compositions with Cannabis Extracts
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
US11964956B2 (en) 2012-09-06 2024-04-23 Northeastern University Cannabinergic compounds and uses thereof
WO2014039042A1 (en) 2012-09-06 2014-03-13 Northeastern University Novel cannabinergic compounds and uses thereof
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
KR101892078B1 (ko) * 2012-10-24 2018-08-28 한국해양과학기술원 로바스틴을 함유하는 뇌암의 예방 또는 치료용 약학 조성물 및 이를 이용한 뇌암의 치료를 위한 병용요법
US20140176689A1 (en) * 2012-12-21 2014-06-26 Samsung Electronics Co. Ltd. Apparatus and method for assisting the visually impaired in object recognition
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
US9199960B2 (en) * 2013-05-02 2015-12-01 Frederick R. Ferri Method and apparatus for processing herbaceous plant materials including the cannabis plant
US9333229B2 (en) 2013-10-16 2016-05-10 William Bjorncrantz Winterized crude cannabis extracts and methods of preparation and use
US9597279B2 (en) 2014-02-28 2017-03-21 HDDC Holdings, LLC Anti-aging dermal composition comprising herbal extracts
EP3160445B1 (de) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi-verwandte produkte und verfahren zur verwendung
RU2723335C2 (ru) 2014-06-30 2020-06-09 Сике Медикал Лтд. Дозовый картридж для ингалятора
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
RU2721064C2 (ru) 2014-06-30 2020-05-15 Сике Медикал Лтд. Ингалятор с регулированием потока
AU2015283589B2 (en) 2014-06-30 2019-09-12 Syqe Medical Ltd. Method and device for vaporization and inhalation of isolated substances
WO2016103254A1 (en) 2014-12-21 2016-06-30 One World Cannabis Ltd Use of cannabis to treat psoriasis
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
EP3368014B1 (de) * 2015-10-26 2023-10-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Neuartige cannabinoidformulierungen
CA3009599A1 (en) 2016-01-06 2017-07-13 Syqe Medical Ltd. Low dose therapeutic treatment
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
JP2019523282A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US10857107B2 (en) * 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
EP3592346A4 (de) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) Zusammensetzungen und verfahren zur behandlung von krebs
BR112019019966A2 (pt) 2017-03-24 2020-04-28 Trait Biosciences Inc biossíntese in vivo de alto nível e isolamento de canabinoides solúveis em água em sistemas de plantas
US11905543B2 (en) 2017-07-11 2024-02-20 Trait Biosceinces, Inc. In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures
US11946059B2 (en) 2017-07-11 2024-04-02 Trait Biosciences, Inc. In vivo generation of water-soluble cannabinoids in plant cell suspension cultures
CN111465700A (zh) * 2017-07-11 2020-07-28 特征生物科学公司 在酵母和植物细胞悬浮培养物中产生水溶性大麻素化合物和材料组合物
IL272709B2 (en) 2017-09-08 2024-09-01 Scicann Therapeutics Inc Compositions comprising a cannabinoid and spilanthol
US10368502B2 (en) * 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
AU2019221321B2 (en) 2018-02-15 2025-01-23 Syqe Medical Ltd. Method and inhaler for providing two or more substances by inhalation
AU2019251357B2 (en) * 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
US11351212B2 (en) * 2018-06-18 2022-06-07 Eric Young Method of drying botanicals
CA3111979A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020223510A1 (en) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Cannabinoid compositions and methods of using
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (de) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. Transdermale zusammensetzungen mit cannabidiol (cbd) zur verwendung bei der behandlung von anfallsleiden
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
EP4110045A4 (de) * 2020-02-25 2024-06-05 The Queen's Medical Center Cannabinoidzusammensetzungen
WO2021188983A1 (en) * 2020-03-20 2021-09-23 The Queen's Medical Center Cannabinoid compositions
EP4126913A4 (de) * 2020-03-29 2024-09-18 Akseera Pharma Corp. Wechselwirkung von sars-cov-2-proteinen mit molekularen und zellulären mechanismen von wirtszellen und formulierungen zur behandlung von covid-19
WO2022067078A1 (en) * 2020-09-25 2022-03-31 Mdm Enterprise Solutions Inc. Precision cannabinoid therapy formulations and methods of use
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847290A (en) 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
JP2000078979A (ja) * 1998-09-04 2000-03-21 Taisho Pharmaceut Co Ltd テトラヒドロカンナビノール酸シンターゼ遺伝子
US6730519B2 (en) * 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions

Also Published As

Publication number Publication date
EP1893191A1 (de) 2008-03-05
US20070032544A1 (en) 2007-02-08
WO2005072719A1 (en) 2005-08-11
US20110021617A1 (en) 2011-01-27
IL177219A0 (en) 2006-12-10
EP1893191B1 (de) 2011-10-12
US7807711B2 (en) 2010-10-05
IL177219A (en) 2013-12-31
WO2005072719A8 (en) 2005-10-27
EP1559423A1 (de) 2005-08-03
ES2375362T3 (es) 2012-02-29

Similar Documents

Publication Publication Date Title
ATE527995T1 (de) Medizinische saure cannabinoide
Hashem et al. Polyphenols in farm animals: source of reproductive gain or waste?
Zhu et al. Docking characterization and in vitro inhibitory activity of flavan-3-ols and dimeric proanthocyanidins against the main protease activity of SARS-Cov-2
NZ735216A (en) Oral solid cannabinoid formulations, methods for producing and using thereof
Tasdemir et al. Inhibition of Plasmodium f alciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids
Bodduluru et al. Naringenin ameliorates inflammation and cell proliferation in benzo (a) pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFκB and PCNA expression
Crascì et al. Natural antioxidant polyphenols on inflammation management: Anti-glycation activity vs metalloproteinases inhibition
Lotti et al. Chemical constituents of red Mexican propolis
Khan et al. Antigiardial activity of isoflavones from Dalbergia frutescens bark
Xiao et al. Interaction of dietary polyphenols with bovine milk proteins: Molecular structure–affinity relationship and influencing bioactivity aspects
Luño et al. Antioxidant effect of lemon balm (Melissa officinalis) and mate tea (Ilex paraguensys) on quality, lipid peroxidation and DNA oxidation of cryopreserved boar epididymal spermatozoa
Sepand et al. Ellagic acid confers protection against gentamicin-induced oxidative damage, mitochondrial dysfunction and apoptosis-related nephrotoxicity
MX2020006965A (es) Formulacion farmaceutica oral que comprende cannabinoides y poloxamero.
Sharma et al. Bioactivity, molecular mechanism, and targeted delivery of flavonoids for bone loss
CA2582289C (en) Inhibition of tumour cell migration
Xiao et al. Noncovalent interaction of dietary polyphenols with bovine hemoglobin in vitro: Molecular structure/property–affinity relationship aspects
Katanić et al. Phytochemical analysis and anti-inflammatory effects of Filipendula vulgaris Moench extracts
NO20033950D0 (no) N¶rende farmasöytisk preparat omfattende polyfenoler og anvendelse i behandling av kreft
WO2009125198A3 (en) Cannabis sativa piants rich in cannabi chromene and its acid, extracts thereof and methods of obtaining extracts therefrom
Shoorei et al. Effects of Matricaria chamomilla extract on growth and maturation of isolated mouse ovarian follicles in a three-dimensional culture system
Bidone et al. Antiherpes activity and skin/mucosa distribution of flavonoids from achyrocline satureioides extract incorporated into topical nanoemulsions
Wang et al. A facile synthetic approach to prenylated flavanones: First total syntheses of (±)-bonannione A and (±)-sophoraflavanone A
Raheel et al. Assessment of the cytotoxic and anti-viral potential of aqueous extracts from different parts of Acacia nilotica (Linn) Delile against Peste des petits ruminants virus
PT1687015E (pt) Composições para o tratamento de afecções da cavidade oral e vias respiratórias superiores
Juckmeta et al. Inhibitory effect on β‐hexosaminidase release from RBL‐2H3 cells of extracts and some pure constituents of benchalokawichian, a Thai herbal remedy, used for allergic disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties